Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 191 for your search:
Drug:
cetuximab
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase II/III Randomized Study of Chemoradiotherapy Comprising Cisplatin, Capecitabine, and Radiotherapy With or Without Cetuximab in Patients With Carcinoma of the Esophagus
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
WCTU-SCOPE-1
, EU-20739, EUDRACT-2006-002241-37, ISRCTN47718479, CTA-17853/0202/001-0001, NCT00509561
2.
Phase II/III Randomized Study of Molecular Selection of Chemotherapy Using K-ras Mutation Analysis and Topoisomerase-1 Expression Analysis in Patients With Metastatic or Locally Advanced Colorectal Cancer
Phase:
Phase III, Phase II
Type:
Diagnostic, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
UKM-MRC-FOCUS3-CR12
, FOCUS 3 - CR12, EUDRACT-2008-008323-15, EU-20960, NCT00975897
3.
Phase III Randomized Study of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) With or Without Cetuximab (C225) After Curative Resection for Patients with Stage III Colon Cancer (Note: All Treatment Arms Containing Irinotecan Closed to Accrual as of 6/1/2005)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 69
Sponsor:
NCI
Protocol IDs:
NCCTG-N0147
, ECOG-N0147, N0147, NCT00079274
4.
Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CP02-0452
, NCT00095199
5.
Phase III Randomized Study of Adjuvant Combination Chemotherapy Comprising Oxaliplatin, Leucovorin Calcium, and Fluorouracil With Versus Without Cetuximab in Patients With Completely Resected Stage III Colon Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 74
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
FFCD-PETACC-8
, EU-20547, EUDRACT-2005-003463-23, PETACC-8, MERCK-FFCD-PETACC-8, NCT00265811
6.
Phase III Randomized Study of Cetuximab and/or Bevacizumab in Combination With Either Oxaliplatin, Fluorouracil, and Leucovorin Calcium (FOLFOX) OR Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium (FOLFIRI) in Patients With Previously Untreated Metastatic Adenocarcinoma of the Colon or Rectum (Arm III [Cetuximab and Bevacizumab in Combination With FOLFOX or FOLFIRI] Closed to Accrual as of 09/10/2009)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
CALGB-C80405
, C80405, SWOG-C80405, NCT00265850
7.
5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
Other
Protocol IDs:
FIRE-3
, NCT00433927
8.
Phase III Randomized Study of Chemoradiotherapy Comprising Paclitaxel, Cisplatin, and Radiotherapy With Versus Without Cetuximab in Patients With Locally Advanced Esophageal Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
RTOG-0436
, RTOG 0436, NCT00655876
9.
Phase III Randomized Study of Neoadjuvant and Adjuvant Combination Chemotherapy With Versus Without Cetuximab in Patients With Resectable Colorectal Liver Metastases
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
USCTU-4351
, EPOC, USCTU-EPOC, EUDRACT-2006-003121-82, ISRCTN22944367, EU-20732, NCT00482222
10.
Phase III Randomized Study of Irinotecan Hydrochloride-Based Chemotherapy and Cetuximab With Versus Without Bevacizumab in Patients With Metastatic Colorectal Cancer That Progressed on First-Line Therapy (Treatment Arm III Closed to Accrual as of 4/20/2009)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
SWOG-S0600
, S0600, CALGB-SWOG-S0600, ECOG-SWOG-S0600, CAN-NCIC-SWOG-S0600, NCCTG-SWOG-S0600, NCT00499369
11.
Phase III Randomized Study of High- Versus Standard-Dose Conformal Radiotherapy With Concurrent and Consolidation Chemotherapy Comprising Carboplatin and Paclitaxel in Patients With Newly Diagnosed, Unresectable Stage IIIA or IIIB Non-Small Cell Lung Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
RTOG-0617
, RTOG 0617, NCCTG-N0628, CALGB-30609, NCT00533949
12.
Phase III Randomized Study of Cetuximab With Versus Without Brivanib Alaninate in Patients With Metastatic Colorectal Carcinoma Previously Treated With Combination Chemotherapy
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
CAN-NCIC-CO20
, CO20, CAN-NCIC-CA182009, NCT00640471
13.
Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
EMR 200048-052
, NCT00678535
14.
Phase III Randomized Study of PET/CT Scan-Guided Watchful Waiting Versus Planned Neck Dissection of Locally Advanced Nodal Metastases in Patients Undergoing Chemoradiotherapy For Primary Head and Neck Squamous Cell Carcinoma
Phase:
Phase III
Type:
Diagnostic, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
WMS-PET-NECK
, WMS-PET-NECK, ISRCTN13735240, EU-20856, MREC-07/Q1604/35, UKCRN ID: 3799, NCT00720070
15.
TPF Plus Cisplatin and Radiotherapy vs TPF Plus Cetuximab and Radiotherapy to Treat Head and Neck Cancer.
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Other
Protocol IDs:
TTCC-2007-01
, NCT00716391
16.
Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
EMR 62240-506
, NCT00820755
17.
Phase III Randomized Study of Carboplatin and Paclitaxel or Carboplatin, Paclitaxel, and Bevacizumab With Versus Without Concurrent Cetuximab in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
SWOG-S0819
, S0819, NCT00946712
18.
Phase III Randomized Study of Adjuvant Intensity-Modulated Radiotherapy With Versus Without Cetuximab in Patients With Locally Advanced Resected Squamous Cell Carcinoma of the Head and Neck
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
RTOG-0920
, RTOG-0920, NCT00956007
19.
Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
EUDRACT NUMBER 2009-013402-14
, NCT00999700
20.
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Subjects With KRAS Wild-Type Metastatic Colorectal Cancer
Phase:
Phase III
Type:
Treatment
Status:
Approved-not yet active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
20080763
, ASPECCT, NCT01001377
21.
Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
EMR62241-054
, NCT01012258
22.
Safety Study of Cetuximab, Radiotherapy and Temozolomide in Primary Glioblastoma Multiforme(GERT)
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Other
Protocol IDs:
Eudract-2005-003911-63
, PEI 119/01, NCT00311857
23.
Combined Treatment of Cetuximab and Paclitaxel in Basal Like Breast Carcinoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
cpblb1-HMO-CTIL
, NCT00353717
24.
Phase I/II Study of Erlotinib Hydrochloride and Cetuximab in Patients With Advanced Gastrointestinal, Head and Neck, Non-Small Cell Lung, or Colorectal Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
VU-VICC-GI-0622
, VICC-GI-0622, 6980, NCI-6980, NCT00397384
25.
Phase I/II Study of Neoadjuvant Therapy Comprising Cetuximab, Oxaliplatin, Fluorouracil, and Radiotherapy in Patients With Stage II or III Squamous Cell Carcinoma of the Esophagus
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Other
Protocol IDs:
KRDI-TUM-OE7-432-LOR-0033-I
, EU-20658, EUDRACT-2006-001097-24, NCT00425425
Select All on Page
1
Help with Results
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
RSS
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
